

Inbal Zafir-Lavie, bio

Dr. Zafir-Lavie completed her Ph.D. cum laude in 2010 from the Technion – Israel Institute of Technology, specializing in antibody engineering and cancer immunology. Following her doctoral studies, she joined Bio-Rad as a project leader in the Protein Technologies Unit.

She then moved to Aevi Genomic Medicine, where she led the development of an antibody gene-therapy platform and later served as Israel R&D Site Head. Subsequently, she relocated to Philadelphia, PA, where she worked as a Senior Scientist in Aevi's translational medicine group, collaborating with the Center for Applied Genomics at Children's Hospital of Philadelphia. During her time in the U.S., Dr. Zafir-Lavie focused on developing innovative diagnostic assays and cutting-edge therapeutics for autoimmune diseases.

Upon returning to Israel, Dr. Zafir-Lavie joined Merck Group as a senior scientist, overseeing the transfer of breakthrough academic projects into industry towards IND.

In 2020, she co-founded and became CEO of Nevvia Bio (formerly Gina-Life), where she led the development of a machine-learning platform for the early detection of ovarian cancer and other women's health conditions.

Dr. Zafir-Lavie serves as an Advisory Board member for Arizona State University's Clinical Research Management and Regulatory Science program and is a member of the 8400 Health Network.

With a passion for translational science and innovative problem-solving, Dr. Zafir-Lavie is dedicated to advancing technologies that improve patient outcomes. Dr. Zafir-Lavie is keen to promote technologies for improving healthcare.